

Product Data Sheet

JZP-MA-11

 Cat. No.:
 HY-152148

 CAS No.:
 1672691-50-7

 Molecular Formula:
 $C_{15}H_{17}FN_4O_2S$

 Molecular Weight:
 336.38

Target: MAGL

Pathway: Metabolic Enzyme/Protease

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description JZP-MA-11 is a positron emission tomography (PET) ligand targeting the endocannabinoid α/β -hydrolase domain 6 (ABHD6) enzyme. JZP-MA-11 selectively inhibits ABHD6 with an IC₅₀ value of 126 nM. JZP-MA-11 can cross the blood-brain barrier

(BBB). [18F]JZP-MA-11 has the potential for preclinical evaluation targeting the brain ABHD6 in mice and nonhuman primate

 $(NHP)^{[1]}$.

In Vitro JZP-MA-11 (10 μ M) has no effect on Forskolin (HY-15371)-stimulated cAMP in HEK293 cells expressing CB₁ or CB₂^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo JZP-MA-11 (1.5 mg/kg; IV; 20 min before tracer injection) results in a decrease in radioactivity uptake in ABHD6-rich organs

such as, brain, liver, heart, and kidneys^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL6 mice (female, 10-12-week-old) ^[1]
Dosage:	1.5 mg/kg
Administration:	IV; 20 min before tracer injection
Result:	Resulted in a decrease in radioactivity uptake in ABHD6-rich organs such as, brain, liver, heart, and kidneys.

REFERENCES

[1]. Karine Mardon, et al. Utilizing PET and MALDI Imaging for Discovery of a Targeted Probe for Brain Endocannabinoid α/β -Hydrolase Domain 6 (ABHD6). J Med Chem. 2022 Dec 14.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA